Mega Doctor News
Edinburg, TX – DHR Health Institute for Research and Development is initiating an innovative clinical study to prevent COVID-19 in high-risk patients.
This is the first such study that is designed to provide passive immunity to patients who have immunocompromised status and cannot mount a robust immune response when infected with the SARS-CoV-2 virus.
On December 8, 2021, the U.S. Food and Drug Administration issued an Emergency Use Authorization allowing the use of AstraZeneca’s long-acting antibody EVUSHELD to be used for prevention of COVID-19 in subjects 12 years and older with moderate to severe immunocompromised status before exposure to the virus.
“For various medical reasons, over seven million people in the United States remain vulnerable to moderate to severe infection with the SARS-CoV-2 virus” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “These are patients who are receiving chemotherapy for cancers, immunosuppressive drugs following transplantation and/or for conditions such as rheumatoid arthritis and lupus”.
“These patients despite vaccination, are unable to generate and sustain satisfactory immune response even after receiving booster doses of COVID-19 vaccine” said Rao “Treatment with this long-acting antibody will provide them with protection against SARS-CoV-2 virus for up to 6-9 months”.
If you or your patient is interested to participate in this study, please call 956-342-4896.
